Press

GoodCap Pharmaceuticals and the University of Toronto Awarded NSERC Alliance Grant for Ongoing Research of Low-Dose Psilocybin Drug Formulas Targeting Inflammation and Depressive Disorders

Nov 10 • 2 min read

GoodCap Pharmaceuticals Inc, a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce that the Natural Sciences and Engineering Research Council of Canada (NSERC) has awarded an Alliance Grant to its research partner at the University of Toronto for $237,339, effective October 2022 to be paid through 2023. The research is focused on furthering…

Cybin Provides Progress Update on its CYB004-E Phase 1 Trial

Nov 10 • 2 min read

Cybin Inc. (NEO:CYBN | (NYSE AMERICAN:CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”) has completed dosing for four out of five participant cohorts and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The CYB004-E Phase 1…

Tryp Therapeutics Announces Poster Presentations on the Reduction of Chronic Pain in a Rodent Model with Psilocybin and Intravenous Psilocybin Alters Brain Network Dynamics in Rats at the 2022 Society for Neuroscience Conference

Nov 10 • 3 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company’s collaborators from the University of Michigan will present two scientific posters in the upcoming Society for Neuroscience (SfN) Conference, to be held from November 12-16, 2022 in…

Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York

Nov 10 • 4 min read

Awakn Life Sciences Corp. (NEO: AWKN | OTCQB: AWKNF | FSE: 954), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces it has signed its third Licensing Partnership agreement in North America. The agreement is with Nushama a leading network of ketamine-assisted therapy centers…

Irwin Naturals Looks to Add Pacific Northwest Ketamine Clinic to Its National Footprint

Nov 10 • 4 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) has reached a binding, arm’s length agreement to acquire the assets of Tri-Cities Infusion & Wellness Clinic, PLLC on November 5, 2022 which is located in Kennewick, Washington. This will be the first facility in Washington for Irwin Naturals Emergence, a fast-growing national chain of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435